Media, page-463

imo Treibel and Voight are hell bent on putting
the potential diversity of EFTI on a platform
that won’t be undervalued….Recent raising lends
itself to giving immutep time to prove the value
of efti in late stage trials whilst broadening the
base in which efti is being researched in, it’s all
about taking advantage of the hard work done
so far whilst researching new parameters…
$2B would be a very disappointing value in my mind,
there are too many variables with unknown values
that can’t be factored into meaningful buyout discussions…